KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.

Patrick Rossignol, Martine Clozel, Roland F Dreier, John M Flack, Bruno Flamion, Johannes Mann, Krzysztof Narkiewicz, Mouna Sassi-Sayadi, Ji-Guang Wang, Michael A Weber, Markus P Schlaich

Hypertension 83(2) e25563

PMID41363010
PMCIDPMC12822777
DOI10.1161/HYPERTENSIONAHA.125.25563
发表日期2025-12-09
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:研究设计图;Figure 3:研究设计图;Figure 4:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Hypertension is a cause and consequence of chronic kidney disease (CKD). Resistant hypertension is common and often difficult to control in patients with CKD. This post hoc analysis evaluated the efficacy and safety of aprocitentan (with standardized background antihypertensive therapy) in patients with CKD and resistant hypertension, a group with high morbidity and mortality risk and limited treatment options. METHODS: The PRECISION study (Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension) consisted of part 1: 4-week, double-blind (aprocitentan 12.5 and 25 mg versus placebo); part 2: 32-week, single-blind (aprocitentan 25 mg); and part 3: 12-week, double-blind withdrawal (aprocitentan 25 mg versus placebo). In participants with CKD, aprocitentan's effect on blood pressure (BP), urine albumin-to-creatinine ratio, and safety was evaluated. RESULTS: Of 730 participants in PRECISION, 147 had CKD categorized as KDIGO high risk or very high risk. At week 4, aprocitentan 12.5 mg, aprocitentan 25 mg, and placebo reduced office systolic BP by -13.5, -16.6, and -4.4 mm Hg, respectively; this was maintained with aprocitentan 25 mg to week 36 (-16.4 mm Hg). At week 4, reductions in nighttime ambulatory systolic BP were -9.6, -13.8, and -2.5 mm Hg, respectively. Changes in urine albumin-to-creatinine ratio were -47.1%, -59.6%, and -2.4%, respectively, maintained with aprocitentan 25 mg to week 36 (-61.6%). Aprocitentan was generally well tolerated (no change in potassium or estimated glomerular filtration rate); early peripheral edema was the most common adverse event. CONCLUSIONS: Aprocitentan was well tolerated; efficiently lowered BP, particularly nighttime ambulatory BP; and markedly reduced urine albumin-to-creatinine ratio in participants with CKD and resistant hypertension. Aprocitentan may confer considerable cardiovascular and kidney-protective benefits in these difficult-to-treat patients. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03541174.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Efficacy of aprocitentan on unattended office systolic blood pressure at trough (SiSBP) over time in participants with Kidney Disease Improving Global Outcomes (KDIGO) ≥high risk and resistant hypertension. Mean SiSBP over time with aprocitentan 12.5 mg, aprocitentan 25 mg, and placebo was measured at trough as unattended automated office blood pressure before treatment administration (study treatment and the standardized background antihypertensive therapy). Error bars are SEM. The subgroup KDIGO ≥high risk includes participants enrolled in PRECISION (Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension) categorized as high risk or very high risk based on the KDIGO criteria. Please refer to Figure S1 for details on the 3-part study design of PRECISION. *Mean change (±SE) from baseline (BL), mm Hg. † Mean change (±SE) from the double-blind withdrawal (DB-WD) BL at week 36, mm Hg; mean SiSBP at the DB-WD BL was 140.0±2.7 mm Hg in participants rerandomized to placebo (n=46) and 139.6±2.3 mm Hg in participants continuing aprocitentan 25 mg (n=64).
非 KM Figure
Figure 2Figure 2. Efficacy of aprocitentan on daytime and nighttime systolic blood pressure (SBP) in participants with Kidney Disease Improving Global Outcomes (KDIGO) ≥high risk and resistant hypertension. Mean change in daytime and nighttime ambulatory SBP from baseline (BL) to week 4 and from the double-blind withdrawal (DB-WD) BL (week 36) to week 40 with aprocitentan 12.5 mg, aprocitentan 25 mg, and placebo was measured by 24-hour ambulatory blood pressure monitoring after treatment administration (study treatment and the standardized background antihypertensive therapy). Error bars are SEM. The subgroup KDIGO ≥high risk includes participants enrolled in PRECISION (Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension) categorized as high risk or very high risk based on the KDIGO criteria. Please refer to Figure S1 for details on the 3-part study design of PRECISION.
非 KM Figure
Figure 3Figure 3. Efficacy of aprocitentan on urine albumin-to-creatinine ratio (UACR) over time in participants with Kidney Disease Improving Global Outcomes (KDIGO) ≥high risk and resistant hypertension. Mean percentage change in UACR over time from baseline (BL) to week 36 and from the double-blind withdrawal (DB-WD) BL (week 36) to week 48 with aprocitentan 12.5 mg, aprocitentan 25 mg, and placebo. UACR was measured on spot urine samples on the morning after treatment administration (study treatment and the standardized background antihypertensive therapy). Error bars are 95% CI. The subgroup KDIGO ≥high risk includes participants enrolled in PRECISION (Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension) categorized as high risk or very high risk based on the KDIGO criteria. Please refer to Figure S1 for details on the 3-part study design of PRECISION. *UACR at BL or DB-WD BL, geometric mean (95% CI), mg/g. † UACR geometric mean (95% CI) percentage change from BL, %. ‡ UACR geometric mean (95% CI) percentage change from the DB-WD BL at week 36, %.
非 KM Figure
Figure 4Figure 4. Subgroup analyses for change from baseline to week 4 in unattended office systolic blood pressure at trough (SiSBP), nighttime systolic blood pressure (SBP), and urine albumin-to-creatinine ratio (UACR) in subgroups with kidney impairment and resistant hypertension. Forest plots of the placebo-corrected least square (LS) mean (95% CI) change in SiSBP ( A ), change in nighttime ambulatory SBP ( B ), and percentage change in UACR ( C ) from baseline to week 4 with aprocitentan 12.5 mg and aprocitentan 25 mg. SiSBP (mm Hg) was measured at trough as unattended automated office blood pressure before treatment administration (study treatment and the standardized background antihypertensive therapy). Nighttime SBP (mm Hg) was measured by 24-hour ambulatory blood pressure monitoring after treatment administration. UACR (% change) was measured on spot urine samples on the morning after treatment administration. The geometric ratio of UACR was transformed to a percentage change ([ratio−1]*100). The Kidney Disease Improving Global Outcomes (KDIGO) ≥high risk subgroup includes participants enrolled in PRECISION (Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension) and categorized as high risk or very high risk based on the KDIGO criteria. Chronic kidney disease (CKD) stage 3a/b is defined as estimated glomerular filtration rate (eGFR) ≥30 to <60 mL/min per 1.73 m 2 , and CKD stages 3 and 4 are defined as eGFR ≥15 to <60 mL/min per 1.73 m 2 . Subgroups defined by albumin levels at baseline include normal albumin levels (UACR <30 mg/g), microalbuminuria (UACR ≥30 to ≤300 mg/g), and macroalbuminuria (UACR >300 mg/g). Colored dashed vertical lines indicate the LS mean of the overall study population for aprocitentan 12.5 mg (light blue) and aprocitentan 25 mg (dark blue) as reference; the gray dashed vertical line indicates the effect threshold.
非 KM Figure